Heterogeneity of serotonergic response in treatment-refractory schizophrenia patients

被引:14
|
作者
Lindenmayer, JP
Adityanjee
VitalHerne, M
Bark, N
Grochowski, S
Moynihan, N
机构
[1] VET ADM MED CTR,SCHIZOPHRENIA PROGRAM,DAYTON,OH
[2] ALBERT EINSTEIN COLL MED,BRONX PSYCHIAT CTR,SCHIZOPHRENIA RES UNIT,BRONX,NY 10467
关键词
metachlorophenylpiperazine; schizophrenia; clozapine; cortisol response; treatment refractory; serotonin;
D O I
10.1016/S0006-3223(96)00296-X
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Oral metachlorophenylpiperazine (m-CPP) as a direct-acting postsynaptic serotonergic agonist was used to study serotonergic dysfunction in treatment-refractory chronic schizophrenia based on the hypothesis that some patients may show central serotonergic hypersensitivity, Seventeen DSM-III-R chronic schizophrenic patients with a history of neuroleptic nonresponse underwent double-blind challenge with oral m-CPP (0.25 mg/kg body weight) and placebo after medication washout, m-CPP significantly elevated both prolactin and cortisol levels as compared to placebo. There was a significant relationship between change in cortisol level and change in psychopathology under m-CPP; a blunted cortisol response was associated with a decrease in total psychopatholoy, while an increase in cortisol response related to an increase in psychopathology. Similarly, decrease in severity of the activation factor and the hostility factor was associated with a smaller cortisol response in the m-CPP condition. These results point to heterogeneity in central serotonergic sensitivity within the context of different subpopulations of serotonergic receptors. (C) 1997 Society of Biological Psychiatry.
引用
收藏
页码:6 / 12
页数:7
相关论文
共 50 条
  • [21] A CARBAMAZEPINE TRIAL IN CHRONIC, TREATMENT-REFRACTORY SCHIZOPHRENIA
    SRAMEK, J
    HERRERA, J
    COSTA, J
    HEH, C
    TRANJOHNSON, T
    SIMPSON, G
    AMERICAN JOURNAL OF PSYCHIATRY, 1988, 145 (06): : 748 - 750
  • [22] Clozapine plasma levels and dosing strategies in patients with treatment-refractory schizophrenia
    Buckley, P
    Cola, P
    Hasegawa, M
    Lys, C
    Thompson, P
    IRISH JOURNAL OF PSYCHOLOGICAL MEDICINE, 1997, 14 (03) : 85 - 88
  • [23] Melperone in treatment-refractory schizophrenia: a case series
    Whiskey, Eromona
    Vavrova, Marta
    Gaughran, Fiona
    Taylor, David
    THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2011, 1 (01) : 19 - 23
  • [24] Atypical antipsyshotic drugs in treatment-refractory schizophrenia
    Bradford, DW
    Chakos, MH
    Sheitman, BB
    Lieberman, JA
    PSYCHIATRIC ANNALS, 1998, 28 (11) : 618 - +
  • [25] Ziprasidone vs chlorpromazine in treatment-refractory schizophrenia
    Giller, EL
    Khanna, S
    Rajadhyaksha, S
    Kane, J
    BIOLOGICAL PSYCHIATRY, 2003, 53 (08) : 187S - 188S
  • [26] Behavioral Treatment of Attentional Dysfunction in Chronic, Treatment-Refractory Schizophrenia
    Steven M. Silverstein
    Debra L. Pierce
    Mari Saytes
    Lisa Hems
    Lindsay Schenkel
    Nancy Streaker
    Psychiatric Quarterly, 1998, 69 : 95 - 105
  • [27] A pharmacoeconomic analysts of clozapine therapy in treatment-refractory schizophrenia
    Konicki, PE
    Manuel, M
    Kwon, K
    Jurjus, G
    Jaskiw, GE
    SCHIZOPHRENIA RESEARCH, 1997, 24 (1-2) : 186 - 186
  • [28] Behavioral treatment of attentional dysfunction in chronic, treatment-refractory schizophrenia
    Silverstein, SM
    Pierce, DL
    Saytes, M
    Hems, L
    Schenkel, L
    Streaker, N
    PSYCHIATRIC QUARTERLY, 1998, 69 (02) : 95 - 105
  • [29] Resistance is not futile: treatment-refractory schizophrenia - overview, evaluation and treatment
    Faden, Justin
    Citrome, Leslie
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (01) : 11 - 24
  • [30] Effects of clozapine on cognitive functions in treatment-refractory schizophrenia
    Stone, WS
    Seidman, LJ
    Kalinowski, A
    Shagrin, B
    Patel, JK
    Shafa, R
    Canuso, C
    Schildkraut, JJ
    Green, AI
    SCHIZOPHRENIA RESEARCH, 1997, 24 (1-2) : 188 - 189